ArticleJournal of oral biology and craniofacial research
Amnion mesenchymal stem cell metabolites reduce inflammation in diabetic salivary gland defect rat models.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Hyposalivation or xerostomia are well-established intraoral complications of diabetes mellitus (DM). Amniotic Mesenchymal Stem Cell Metabolite Products (AMSC-MPs) are being widely studied for their immunomodulatory action. However, their potential in a salivary gland defect model has yet to be explored. This study aims to determine the potential of AMSC-MPs in modulating the inflammatory response in the salivary glands of rats with persistent hyperglycemia, mimicking the pathogenesis of salivary gland disorders in DM. Methods: Forty-eight male pre-conditioned diabetic rats were divided into treatment and control groups. The treatment group received AMSC-MPs intraglandular injections, while the control group received phosphate-buffered saline intraglandular injections. Both groups were injected for 3, 5, 7, and 10 consecutive days. Subsequently, the submandibular salivary glands were biopsied and processed for formalin-fixed paraffin-embedded tissue for immunohistochemical assessment. The inflammatory response was assessed by quantifying the expression of tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), and transforming growth factor β (TGF-β). Results: This study found significant downregulation of inflammatory cytokines, TNF-α and IL-6, in the AMSC-MPs intraglandular injections compared to the control (p < 0.05). Moreover, IL-10 and TGF-β expression, which may act as anti-inflammatory cytokines in this pathology, was significantly upregulated compared to the control (p < 0.05). Conclusion: Our study demonstrated the anti-inflammatory potential of AMSC-MPs intraglandular injections in a diabetes-induced salivary gland defect rat model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.